This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bourin, M. Articles by Malinge, M. Search for Related Content PubMed Articles by Bourin, M. Articles by Malinge, M. Social Bookmarking                         What's this?

Lorazepam 0.25 mg twice a day improves aspects of psychometric performance in healthy volunteers

Department of Pharmacology and GIS Médicament, Faculty of Medicine, 44035 Nantes cedex 01, France

Marie-Claude Colombel

Department of Pharmacology and GIS Médicament, Faculty of Medicine, 44035 Nantes cedex 01, France

Myriam Malinge

Department of Pharmacology and GIS Médicament, Faculty of Medicine, 44035 Nantes cedex 01, France

The effects of lorazepam (0.25 mg) twice a day on several cognitive and performance tasks, pictures test, digit-symbol substitution test (DSST), choice reaction time (CRT) and critical flicker fusion (CFF), were investigated in healthy students. A double-blind independent group design was used to compare placebo and lorazepam (30 volunteers in each group). After randomisation, all subjects received placebo for 3 days (D), followed by 14 days of treatment, with either lorazepam or placebo. Subjects completed a battery of tests at Do, then D₃, D₇ , D₁₀ and D₁₄. D₃ performance was poorer in the lorazepam group except for CFF (ascending values and total values), yet the only significant improvement was in total reaction time on the CRT test. However, a significant improvement of performance was shown at D₇, D₁₀ and D₁₄ in the lorazepam group compared with the control group (except in recognition reaction time). The current study shows that low repeated doses of lorazepam are able to produce small improvements in some aspects of psychomotor and cognitive functions in healthy volunteers. Different points are discussed to explain the performance improvement: training effect, tolerance effect, partial inverse agonist effect and the possible release of cholecystokinin.

Key Words: healthy subjects • lorazepam • psychomotor performance

Journal of Psychopharmacology, Vol. 9, No. 3, 251-257 (1995)
DOI: 10.1177/026988119500900308


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?